Anthem Biosciences IPO is generating buzz after being subscribed 63.86x during the July 14–16 issue period. With strong anchor backing of ₹1,016 crore and a fully-offer-for-sale (OFS) structure, the listing on July 21 could pave the way for a sharp upside. Experts eye a listing price at 540–570 rupees and potential 25% premium, based on grey-market premium (GMP) in the 138–156 range.

This is not just hype—sector fundamentals support the optimism. As one of India’s top CRDMOs (Contract Research, Development & Manufacturing Organisations), Anthem serves global pharma clients with fermentation-based APIs like peptides, probiotics, biosimilars, and enzymes.

💡 Expert Insights: Holding or Booking Profits?

Niranjan Solanki of Anand Rathi notes that based on FY25 earnings, the stock trades at a reasonable PE of 70.6×. With market cap around ₹31,867 crore and robust margins, he advises long-term investors to hold post-listing.

Mahesh M. Ojha, AVP at Hensex Securities, suggests institutional demand may propel listing to ₹700 or higher—a 20–25% jump. He recommends swing traders book early profits, while long-term investors monitor margin trends, innovation, and client growth.

Harshal Dasani of INVasset PMS adds that if Q2 earnings remain strong and listing matches grey-market expectations, Anthem could become a cornerstone in India’s biotech revolution.

🧪 Business Overview: Why the Buzz Around Anthem?

Anthem Biosciences is a Bengaluru-based CRDMO that delivers end-to-end services in drug discovery, development, and manufacturing. Major offerings include:

• Fermentation-based APIs: peptides, vitamins, probiotics
• Biosimilars and enzymes
• Extensive global client reach in pharmaceutical and biotech
• High growth backed by increasing demand in Indian contract manufacturing

These capabilities align with India’s ambition to become a global biotech hub. Firms like Anthem play a critical role in reduced dependency on imports and scaling domestic capacity.

🔍 Listing Strategy: Should Non-Allottees Go In?

If you missed the IPO allotment, here’s what to weigh:

• Watch the listing price: Market feedback and grey-market demand hint at 25% premium; wait for stability before entry.
• Follow Q2 updates: Keep tabs on earnings, margin trends, and client additions.
• Compare with peers: Analyze valuations against global CRDMOs to ensure it’s not fully priced.

Non-allottees may benefit more by watching for dips post-listing and deploying capital after confirmation of momentum.

📊 What Happens on July 21?

Date to watch: July 21 is the listing day. Positive listing near the upper end might create initial euphoria, possibly offering short-term gains. But for lasting value, fundamentals like consistent revenue growth, margin resilience, and new global clients will steer the long-term trend.

✅ Final Take: Is Anthem IPO a Smart Play?

Anthem Biosciences IPO appears to be a compelling opportunity for both traders and long-term investors. With strong sector credentials, institutional backing, and attractive grey-market pricing, it’s worth watching closely. Traders may profit from short-lived listing impact, while long-term investors should track strategic KPIs before jumping in.

For a peer comparison and sector insight, explore this CRDMO analysis report from IBEF (India Brand Equity Foundation) with a do-follow link to deepen understanding of the contract manufacturing landscape.

Also Read

• Q1 Results: This PSU Bank Surprises with Profit Jump — What the Numbers Hide Will Shock You!
• Q1 Results Shock: This Bank Beats Profit Estimates but Faces a Hidden Risk
•  Q1 Results Shock: This Cement Giant Swings From Profit to Loss – What Went Wrong?
•  RBL Bank Q1 Results: What the 46% Profit Dip Really Means for Investors 
• Q1 Results Shock: This PSU Reports Unexpected Loss — What Investors Should Know Before Monday

The information provided here is ai generated and for general information and educational purposes only. It is not intended to be personalized investment advice, nor should it be considered as a solicitation to buy or sell any security or financial product.